Humacyte Inc (HUMA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Humacyte Inc stock (HUMA) is currently trading at $0.82. Humacyte Inc PS ratio (Price-to-Sales) is 96.18. Analyst consensus price target for HUMA is $7.71. WallStSmart rates HUMA as Sell.
- HUMA PE ratio analysis and historical PE chart
- HUMA PS ratio (Price-to-Sales) history and trend
- HUMA intrinsic value — DCF, Graham Number, EPV models
- HUMA stock price prediction 2025 2026 2027 2028 2029 2030
- HUMA fair value vs current price
- HUMA insider transactions and insider buying
- Is HUMA undervalued or overvalued?
- Humacyte Inc financial analysis — revenue, earnings, cash flow
- HUMA Piotroski F-Score and Altman Z-Score
- HUMA analyst price target and Smart Rating
Humacyte Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Humacyte Inc (HUMA) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Humacyte Inc (HUMA) Key Strengths (0)
Supporting Valuation Data
Humacyte Inc (HUMA) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Very expensive at 96.2x annual revenue
Very expensive at 57.8x book value
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 30.53%
Supporting Valuation Data
Humacyte Inc (HUMA) Detailed Analysis Report
Overall Assessment
This company scores 12/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (96.18), Price/Book (57.77) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -249.80%, Operating Margin at -3239.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -249.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HUMA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HUMA's Price-to-Sales ratio of 96.18x trades at a deep discount to its historical average of 488.06x (0th percentile). The current valuation is 94% below its historical high of 1624.49x set in Sep 2021, and 0% above its historical low of 96.18x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~241.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Humacyte Inc (HUMA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Humacyte Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 2M with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 1099% of revenue (17M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -24M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.93, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Humacyte Inc.
Bottom Line
Humacyte Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Humacyte Inc(HUMA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Humacyte Inc (HUMA) is a leading biotechnology company focused on transforming vascular and regenerative medicine through its development of innovative human acellular vessels (HAVs). By addressing the urgent clinical needs for vascular reconstruction and the treatment of chronic diseases, Humacyte aims to deliver off-the-shelf solutions that enhance patient outcomes and reduce healthcare costs. Leveraging its advanced technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, ultimately making a substantial impact on the future of medical therapies.